Novartis, Aster sign MoU

Novartis, a global medicines company, and Aster DM Healthcare, one of the region’s largest healthcare providers, have signed an MoU in the areas of digital transformation and clinical research.

Aster, which has a large network of hospitals, clinics and pharmacies in seven countries, will have access to the advanced therapy platforms and data science of Novartis, a global leader investing in research and development.

“Data Analytics with focus on clinical research is one of the cornerstones of healthcare in future. Aster tries to stay ahead of the curve. We have associated with Novartis in the past and are glad to enter into a multi-faceted partnership to enhance Digital Transformation and Research,” said Dr. Azad Moopen, Founder Chairman and Managing Director, Aster DM Healthcare.

The collaboration aims to identify the gaps in patient care and to introduce extensive medical programmes using innovative data platforms and data syndicated designs. 

“We are happy to collaborate with Aster to realise their vision towards data transformation and clinical research, both of which are tantalising growth areas for the healthcare sector,” said Mohamed Ezz Eldin, President and Head of Gulf Cluster, Novartis Pharmaceuticals.

As a part of the collaboration, Novartis will enable data generation, ideation, and impactful decision making for Aster DM Healthcare’s clinical research program. The organisations have plans to initiate a series of workshops, trainings, and educational activities, which will assist Aster to commence its activities on clinical research, said a joint release.

The digital transformation initiatives will also separately work on boosting the digital healthcare strategy of Aster DM Healthcare for its market in UAE and beyond, whereas Novartis will provide its expertise and share best practices.